DOCSLIB.ORG

Highlights in Lymphoma from the 2013 American Society Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Highlights in Lymphoma from the 2013 American Society Of February 2014 Volume 12, Issue 2, Supplement 6 A SPECIAL MEETING REVIEW EDITION Highlights in Lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition A Review of Selected Presentations From the 2013 American Society of Hematology Annual Meeting and Exposition • December 7-10, 2013 • New Orleans, Louisiana Special Reporting on: • A Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients With DLBCL and Other B-Cell Lymphomas • A Phase I Study of Panobinostat in Combination With ICE (Ifosfamide, Carboplatin and Etoposide) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) • FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed by Autologous Stem Cell Transplant for Relapsed and Refractory Hodgkin Lymphoma • Mature Response Data From a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) • Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoprolif- erative Disorders • Lenalidomide in Combination With R-CHOP (R2-CHOP) in Patients With High Burden Follicular Lymphoma: Phase 2 Study • Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM) • Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle Cell Lym- phoma: Multi-Center Phase II Study of Lenalidomide Plus Rituximab PLUS Meeting Abstract Summaries With Expert Commentary by: Nancy L. Bartlett, MD Professor of Medicine Koman Chair in Medical Oncology Washington University School of Medicine St Louis, Missouri ON THE WEB: hematologyandoncology.net Indexed through the National Library of Medicine (PubMed/MEDLINE), PubMed Central (PMC), and EMBASE PHASE 3 TRIAL NOW RECRUITING Assessing brentuximab vedotin in Frontline Peripheral T-cell Lymphomas Consider ECHELON-2 when making a treatment plan Patients Investigational arm † Endpoints CD30-positive mature (peripheral) A+CHP regimen (6-8 cycles) T-cell lymphomas, including Brentuximab vedotin Primary endpoint systemic ALCL (N = 300)* 1.8 mg/kg IV on day 1 of each 21-day cycle, plus placebo • Progression-free Select inclusion criteria: replacement for vincristine survival (PFS) • Newly diagnosed • Measurable disease, as defined by both of the Standard arm Secondary endpoints following: • Overall survival † – FDG-avid disease by PET CHOP regimen (6-8 cycles) • Overall response rate 2 – CT tumor burden ≥1.5 cm Vincristine 1.4 mg/m IV on • Safety and tolerability • ECOG performance day 1 of each 21-day cycle, status 0 to 2 plus placebo replacement for brentuximab vedotin * Eligible subtypes include anaplastic lymphoma kinase (ALK)–positive systemic anaplastic large cell lymphoma (ALCL) with an International Prognostic Index (IPI) score of ≥2; ALK-negative systemic ALCL; peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL); adult T-cell leukemia/lymphoma (ATLL); enteropathy-associated T-cell lymphoma (EATL); and hepatosplenic T-cell lymphoma. † Cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 will be administered IV on day 1; 100 mg oral prednisone will be administered on days 1-5 of each 21-day cycle. To learn more about ECHELON-2 Eligible patients must or refer a patient: be treatment-naïve • Contact Seattle Genetics Medical Information at 866.333.7436 (US only) STOP BEFORE • E-mail [email protected] CHOP • Visit clinicaltrials.gov (NCT01777152) seattlegenetics.com MILLENNIUM and are registered trademarks Seattle Genetics and are US registered trademarks of Seattle Genetics, Inc. of Millennium Pharmaceuticals, Inc. Other trademarks are property of their respective owners. Other trademarks are property of their respective owners. © 2013 Seattle Genetics, Inc., Bothell, WA 98021 Millennium Pharmaceuticals, Inc., Cambridge, MA 02139 All rights reserved. Printed in USA USM/BVM/2013/0235a Copyright © 2013, Millennium Pharmaceuticals, Inc. All rights reserved. 20808_sgn35_fa1_ech_bld.indd 1 1/29/14 12:07 PM PHASE 3 TRIAL HIGHLIGHTS IN LYMPHOMA FROM THE 2013 ASH ANNUAL MEETING AND EXPOSITION NOW RECRUITING A Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients With DLBCL and Other B-Cell Lymphomas Assessing brentuximab vedotin in utcomes for patients with relapsed or refractory dif- 150 Other (n=17) DLBCL (n=41) Fatigue 43% Frontline Peripheral T-cell Lymphomas fuse large B-cell lymphoma CR O(DLBCL) remain poor; autologous stem 100 cell transplant (ASCT) yields limited Nausea 43% 50 Consider ECHELON-2 when making a treatment plan efficacy in the rituximab era, and there is Grade 1/2 no standard of care for patients who are 81% of patients achieved tumor reduction 0 Vomiting 29% Grade 3 Patients Investigational arm ineligible for transplant.1 Brentuximab Tumor Size Tumor Grade 4 vedotin is an antibody-drug conjugate † Endpoints -50 CD30-positive mature (peripheral) A+CHP regimen (6-8 cycles) consisting of a CD30-directed mono- Febrile neutropenia 10% T-cell lymphomas, including Brentuximab vedotin clonal antibody linked with the micro- Baseline) From (% Change Primary endpoint -100 systemic ALCL (N = 300)* 1.8 mg/kg IV on day 1 of each tubule-disrupting agent monomethyl Anemia 24% 5% • Progression-free Individual Patients (n=58) Major Toxicities 21-day cycle, plus placebo auristatin E (MMAE). Brentuximab Select inclusion criteria: replacement for vincristine survival (PFS) vedotin has demonstrated high response • Newly diagnosed Neutropenia 5% 10% 57% rates in patients with CD30-expressing Figure 1. Interim results from a phase 2 study of brentuximab vedotin in patients • Measurable disease, as defined by both of the Standard arm Secondary endpoints B-cell malignancies, including Hodgkin with relapsed or refractory CD30-positive non-Hodgkin lymphomas showed that 5% 10% 81% (84% in A, 50% in B) following: • Overall survival lymphoma and systemic anaplastic large approximately 81% of patients had some degree of tumor reduction. CR, complete Thrombocytopenia † 2,3 response; DLBCL, diffuse large B-cell lymphoma. Adapted from Bartlett NB et al. ASH – FDG-avid disease by PET CHOP regimen (6-8 cycles) cell lymphoma. Recent studies indicate • Overall response rate abstract 848. Blood. 2013;122(21 suppl).6 0 10 20 30 40 50 60 70 80 90 100 – CT tumor burden ≥1.5 cm Vincristine 1.4 mg/m2 IV on that between 14% and 25% of DLBCLs • Safety and tolerability Patients With Events (%) • ECOG performance day 1 of each 21-day cycle, express CD30, including both activated leukemia. The median age was 63 years In the study, brentuximab vedotin plus placebo replacement for status 0 to 2 B-cell type and germinal center subtypes, (range, 17-85 years) amongWeekly patients BV x2was cycles associated46 with enrolled an (45 overall eligible) response brentuximab vedotin and CD30 expression is associated with with DLBCL and 36 years (range, 16-68 rate (ORR) of 42% in patients with a more favorable prognosis.4,5 years) among the other patients. Patients DLBCL, including 16% complete 30 pts 12 pts Based on these demonstrations of had received a median of 2 to 3 prior responses (CRs), and 22% in patients * Eligible subtypes include anaplastic lymphoma kinase (ALK)–positive systemic anaplastic large cell lymphoma (ALCL) with an International Prognostic 42 pts Index (IPI) score of ≥2; ALK-negative systemic ALCL; peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); angioimmunoblastic T-cell CD30 positivity, a phase 2 study was systemic therapies, with 20% of patients with other histologies, including 11% Augmented ICE x2 (11 pts) lymphoma (AITL); adult T-cell leukemia/lymphoma (ATLL); enteropathy-associated T-cell lymphoma (EATL); and hepatosplenic T-cell lymphoma. undertaken evaluating brentuximab receiving a prior ASCT.cycles The majority of CRs. The median durations of response vedotin in patients with CD30-positive patients (74% of those with DLBCL and and CR were 5.8 months and 11.5 † 2 2 100 Cyclophosphamide 750 mg/m and doxorubicin 50 mg/m will be administered IV on day 1; 100 mg oral prednisone will be administered on days 1-5 relapsed or refractory non-Hodgkin lym- 89% of other patients) were refractory to months, respectively, in the DLBCL Median PFS, 11 months of each 21-day cycle. HDT/ASCT phoma (NHL). Results were presented frontline therapy, and 82% and 72% of group and 5.0 months and not reached 21 pts 39 pts transplanted at the 2013 American Society of Hema- patients, respectively,8 pts were refractory to in other patients. Median progression- 75 (1 lost to follow-up) Disease status pretransplant: tology (ASH) meeting by Dr Nancy the most recent prior therapy. free survival (PFS)-34 Deauville was 4.0 2 (2 monthsafter IFRT) in the Bartlett.6 Patients were required to be at Patients were enrolled based on 7 ptsDLBCL group-2 Deauville and 2.9 3 months in other To learn more about ECHELON-2 Further treatment (5 after IFRT) -3 PR (after IFRT) Eligible patients must least 12 years old and to have an Eastern CD30 positivityaccording as demonstrated to treating by patients. Patients received a median of 4 or refer a patient: physician 50 be treatment-naïve Cooperative
Load more

Recommended publications
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • Neuro-Ophthalmic Side Effects of Molecularly Targeted Cancer Drugs
    Eye (2018) 32, 287–301 © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-222X/18 www.nature.com/eye 1,2,3 4 Neuro-ophthalmic side MT Bhatti and AKS Salama REVIEW effects of molecularly targeted cancer drugs Abstract The past two decades has been an amazing time culminated in indescribable violence and in the advancement of cancer treatment. Mole- unspeakable death. However, amazingly within cularly targeted therapy is a concept in which the confines of war have risen some of the specific cellular molecules (overexpressed, greatest advancements in medicine. It is within mutationally activated, or selectively expressed this setting—in particular World War II with the proteins) are manipulated in an advantageous study of mustard gas—that the annals of cancer manner to decrease the transformation, prolif- chemotherapy began touching the lives of eration, and/or survival of cancer cells. In millions of people. It is estimated that in 2016, addition, increased knowledge of the role of the over 1.6 million people in the United States will immune system in carcinogenesis has led to the be diagnosed with cancer and over a half a development of immune checkpoint inhibitors million will die.1 The amount of money being to restore and enhance cellular-mediated anti- spent on research and development of new tumor immunity. The United States Food and cancer therapies is staggering with a record $43 Drug Administration approval of the chimeric billion dollars spent in 2014. Nearly 30% of all monoclonal antibody (mAb) rituximab in 1997 registered clinical trials on the clinicaltrials.gov 1Department of for the treatment of B cell non-Hodgkin lym- website pertain to cancer drugs.
    [Show full text]
  • Whither Radioimmunotherapy: to Be Or Not to Be? Damian J
    Published OnlineFirst April 20, 2017; DOI: 10.1158/0008-5472.CAN-16-2523 Cancer Perspective Research Whither Radioimmunotherapy: To Be or Not To Be? Damian J. Green1,2 and Oliver W. Press1,2,3 Abstract Therapy of cancer with radiolabeled monoclonal antibodies employing multistep "pretargeting" methods, particularly those has produced impressive results in preclinical experiments and in utilizing bispecific antibodies, have greatly enhanced the thera- clinical trials conducted in radiosensitive malignancies, particu- peutic efficacy of radioimmunotherapy and diminished its toxi- larly B-cell lymphomas. Two "first-generation," directly radiola- cities. The dramatically improved therapeutic index of bispecific beled anti-CD20 antibodies, 131iodine-tositumomab and 90yttri- antibody pretargeting appears to be sufficiently compelling to um-ibritumomab tiuxetan, were FDA-approved more than a justify human clinical trials and reinvigorate enthusiasm for decade ago but have been little utilized because of a variety of radioimmunotherapy in the treatment of malignancies, particu- medical, financial, and logistic obstacles. Newer technologies larly lymphomas. Cancer Res; 77(9); 1–6. Ó2017 AACR. "To be, or not to be, that is the question: Whether 'tis nobler in the pembrolizumab (anti-PD-1), which are not directly cytotoxic mind to suffer the slings and arrows of outrageous fortune, or to take for cancer cells but "release the brakes" on the immune system, arms against a sea of troubles, And by opposing end them." Hamlet. allowing cytotoxic T cells to be more effective at recognizing –William Shakespeare. and killing cancer cells. Outstanding results have already been demonstrated with checkpoint inhibiting antibodies even in far Introduction advanced refractory solid tumors including melanoma, lung cancer, Hodgkin lymphoma and are under study for a multi- Impact of monoclonal antibodies on the field of clinical tude of other malignancies (4–6).
    [Show full text]
  • B-Cell Targets to Treat Antibody-Mediated Rejection In
    Muro et al. Int J Transplant Res Med 2016, 2:023 Volume 2 | Issue 2 International Journal of Transplantation Research and Medicine Commentary: Open Access B-Cell Targets to Treat Antibody-Mediated Rejection in Transplantation Manuel Muro1*, Santiago Llorente2, Jose A Galian1, Francisco Boix1, Jorge Eguia1, Gema Gonzalez-Martinez1, Maria R Moya-Quiles1 and Alfredo Minguela1 1Immunology Service, University Clinic Hospital Virgen de la Arrixaca, Spain 2Nephrology Service, University Clinic Hospital Virgen de la Arrixaca, Spain *Corresponding author: Manuel Muro, PhD, Immunology Service, University Clinic Hospital “Virgen de la Arrixaca”, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain, Tel: 34-968-369599, E-mail: [email protected] Antibody-mediated rejection (AMR) in allograft transplantation APRIL (a proliferation-inducing ligand). These co-activation signals can be defined with a rapid increase in the levels of specific are required for B-cell differentiation into plasma cell and enhancing serological parameters after organ transplantation, presence of donor their posterior survival and are a key determinant of whether specific antibodies (DSAs) against human leukocyte antigen (HLA) developing B-cells will survive or die during the establishment molecules, blood group (ABO) antigens and/or endothelial cell of immuno-tolerance [5,6]. Important used agents commercially antigens (e.g. MICA, ECA, Vimentin, or ETAR) and also particular available are Tocilizumab (anti-IL6R) and Belimumab (BAFF). histological parameters [1,2]. If the AMR persists or progresses, the The receptors of BAFF and APRIL could also be important as treatment to eliminate the humoral component of acute rejection eventual targets, for example BAFF-R, TACI (transmembrane include three sequential steps: (a) steroid pulses, antibody removal activator and calcium modulator and cyclophyllin ligand interactor) (plasma exchange or immuno-adsorption) and high doses of and BCMA (B-cell maturation antigen).
    [Show full text]
  • Antibody-Drug Conjugates (Adcs) – Biotherapeutic Bullets
    Sean L Kitson Antibody-Drug Conjugates (ADCs) – Biotherapeutic bullets SEAN L KITSON*, DEREK J QUINN, THOMAS S MOODY, DAVID SPEED, WILLIAM WATTERS, DAVID ROZZELL *Corresponding author Almac, Department of Biocatalysis and Isotope Chemistry, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, United Kingdom (chimeric human-murine IgG1 targeting EGF receptor) and KEYWORDS panitumumab (human IgG2 targeting EGF receptor) for the Antibody-drug conjugate; ADC; monoclonal antibody; treatment of metastatic colorectal cancer (5). cancer; carbon-14; linker; immunotherapy. This technology of tailoring MAbs has been exploited to develop delivery systems for radionuclides to image and treat a variety of cancers (6). This led to the hypothesis that a ABSTRACT cancer patient would first receive a radionuclide antibody capable of imaging the tumour volume. The images of the Immunotherapies especially targeted towards oncology, tumour are obtained by using one or more combinations of based on antibody-drug conjugates (ADCs) have the following methods: planar imaging; single photon recently been boosted by the US Food and Drug emission computed tomography (SPECT) and positron Administration approval of Adcetris to treat Hodgkin’s emission tomography (PET) (7). These techniques can be lymphoma and Kadcyla for metastatic breast cancer. extended to hybrid imaging systems incorporating PET (or The emphasis of this article is to provide an overview of SPECT) with computed tomography (CT) or magnetic the design of ADCs in order to examine their ability to 30 resonance imaging (MRI) (8). find and kill tumour cells. A particular focus will be on the relationship between the cytotoxic drug, chemical The imaging process is first used to locate the precise position linker and the type of monoclonal antibody (MAb) used of the tumour and ascertain the appropriate level of the to make up the components of the ADC.
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • Imatinib (Gleevec™)
    Biologicals What Are They? When Did All of this Happen? There are Clear Benefits. Are there also Risks? Brian J Ward Research Institute of the McGill University Health Centre Global Health, Immunity & Infectious Diseases Grand Rounds – March 2016 Biologicals Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. National Cancer Institute (USA) What Effects Do Steroids Have on Immune Responses? This is your immune system on high dose steroids projects.accessatlanta.com • Suppress innate and adaptive responses • Shut down inflammatory responses in progress • Effects on neutrophils, macrophages & lymphocytes • Few problems because use typically short-term Virtually Every Cell and Pathway in Immune System ‘Target-able’ (Influenza Vaccination) Reed SG et al. Nature Medicine 2013 Nakaya HI et al. Nature Immunology 2011 Landscape - 2013 Antisense (30) Cell therapy (69) Gene Therapy (46) Monoclonal Antibodies (308) Recombinant Proteins (93) Vaccines (250) Other (81) http://www.phrma.org/sites/default/files/pdf/biologicsoverview2013.pdf Therapeutic Category Drugs versus Biologics Patented Ibuprofen (Advil™) Generic Ibuprofen BioSimilars/BioSuperiors ? www.drugbank.ca Patented Etanercept (Enbrel™) BioSimilar Etanercept Etacept™ (India) Biologics in Cancer Therapy Therapeutic Categories • Hormonal Therapy • Monoclonal antibodies • Cytokine therapy • Classical vaccine strategies • Adoptive T-cell or dendritic cells transfer • Oncolytic
    [Show full text]
  • Hodgkin's Lymphoma Unresponsive to Rituximab Or a Rituximab
    Clinical Development GSK1841157 Protocol OMB110918 / NCT01077518 A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non- Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Authors Document type Amended Protocol Version EUDRACT number 2008-004177-17 Version number 11 Development phase III Document status Final Release date 13-Apr-2017 Novartis internal reference number COMB157E2301 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Novartis Confidential Page 2 Amended Protocol Version 11 Clean Protocol No. COMB157E2301/OMB110918 Amendment 9 (13-Apr-2017) Amendment rationale The purpose of amendment 9 is to revise the total number of events required for the primary analysis of the primary end point PFS. The primary analysis was planned after reaching 259 PFS events as determined by an Independent Review Committee (IRC). Based on the current status of the study and PFS event count by IRC, it is highly unlikely that the 259 PFS events will be achieved. The study has been ongoing since September 2010 when the first patient was enrolled and the study sponsorship changed in February 2016 from GSK to Novartis (Amendment 8 , dated 18Mar2016). Per protocol, Interim Analysis for efficacy and futility and IDMC review occurred (22Feb2016) after 180 PFS events by IRC were reached (31Oct2015). IDMC recommended to continue the study without changes. The interim analysis of PFS was performed by an independent Statistical Data Analysis Centre. As per IDMC charter, unblinded results were not communicated to the sponsor in order to maintain the integrity of the trial.
    [Show full text]
  • Ibritumomab Tiuxetan (Zevalin)
    Ibritumomab tiuxetan (Zevalin) Policy Number: Original Effective Date: MM.04.013 03/11/2003 Line(s) of Business: Current Effective Date: HMO; PPO 06/22/2012 Section: Prescription Drugs Place(s) of Service: Outpatient I. Description Ibritumomab tiuxetan (Zevalin) is a CD20-directed radiotherapeutic antibody administered as part of the ibritumomab tiuxetan therapeutic regimen indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL) and for the treatment of patients with previously untreated follicular NHL who have achieved a partial or complete response to first-line chemotherapy. Ibritumomab tiuxetan is comprised of two separate components, indium-111(IN-111) the diagnostic component and yttrium-90 (Y-90) the therapeutic component. The ibritumomab tiuxetan regimen includes the administration of rituximab followed by IN-111, which targets and binds to the tumor cell. If the IN-111 binds successfully to the tumor cells, seven to nine days later, a second dose of rituximab is administered followed by Y-90 which damages the targeted tumor cells. II. Criteria/Guidelines A. The ibritumomab tiuxetan therapeutic regimen is covered (subject to Limitations/Exclusions and Administrative Guidelines) when recommended by an oncologist for the following conditions: 1. Non-Hodgkin’s lymphoma (NHL) a. For the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL b. For the treatment of patients with follicular NHL who achieve a partial or complete response to first-line chemotherapy 2. For the indications listed above, the following criteria must be met: a. Lymphoma involvement of the bone is less than 25 percent Ibritumomab tiuxetan (Zevalin) 2 b.
    [Show full text]
  • Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
    pharmaceutics Review Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Marco Cavaco, Diana Gaspar, Miguel ARB Castanho * and Vera Neves * Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (M.A.R.B.C.); [email protected] (V.N.) Received: 19 November 2019; Accepted: 28 December 2019; Published: 13 January 2020 Abstract: The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.
    [Show full text]
  • Ibritumomab Tiuxetan)
    Zevalin Y-90® (ibritumomab tiuxetan) Last Review Date: July 15, 2019 Number: MG.MM.PH.181 Medical Guideline Disclaimer C All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members.
    [Show full text]
  • Adcetris, INN-Brentuximab Vedotin
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT ADCETRIS 50 mg powder for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 50 mg of brentuximab vedotin. After reconstitution (see section 6.6), each mL contains 5 mg of brentuximab vedotin. ADCETRIS is an antibody-drug conjugate composed of a CD30-directed monoclonal antibody (recombinant chimeric immunoglobulin G1 [IgG1], produced by recombinant DNA technology in Chinese Hamster ovary cells) that is covalently linked to the antimicrotubule agent monomethyl auristatin E (MMAE). Excipient with known effect Each vial contains approximately 13.2 mg of sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. White to off-white cake or powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Hodgkin lymphoma ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1). ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see section 5.1). ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following ASCT, or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
    [Show full text]